SentiBio
senti product candidate protects primary donor while maintaining on target killing of cancer cells eye | SentiBio
Company
Deck Type
Deck date
October 2021
Slide
26 of 52
Related slides by other companies
Absci
Investor Presentation
July 2023
antibodies selected in tertiary lymphoid structures bind to cancer cells and are associated with favorable clinical outcomes | Absci
Genelux
Investor Presentation
December 2023
program builds on completed trials to exploit competitive advantages estimated billion dollar plus annual commercial opportunity us | Genelux
Absci
Investor Presentation
March 2023
antibodies selected in tertiary lymphoid structures bind to cancer cells and are associated with favorable clinical outcomes go | Absci
Absci
Investor Presentation
October 2023
antibodies selected in tertiary lymphoid structures bind to cancer cells and are associated with favorable clinical outcomes | Absci
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights